May 1, 2019 / 12:38 AM / in 21 days

FDA declines to approve Nabriva's antibiotic for urinary tract infections

April 30 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to approve Nabriva Therapeutics Plc’s antibiotic for complicated urinary tract infections (cUTI), even as the nation grapples with the growing problem of antibiotic resistance.

Nabriva’s Contepo, chemically known as fosfomycin, is the first intravenously administered drug from a new class of antibiotics called epoxide in the United States, the company said. At least 2 million Americans develop serious infections from antibiotic-resistant bacteria, resulting in nearly 23,000 deaths annually, according to the Centers for Disease Control and Prevention. (Reporting by Saumya Sibi Joseph, Tamara Mathias and Aakash Jagadeesh Babu in Bengaluru; Editing by Sandra Maler)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below